---
layout: default
title: Repaglinide
parent: 僅模型預測 (L5)
nav_order: 67
evidence_level: L5
indication_count: 0
---

# Repaglinide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Repaglinide: Drug Repurposing Evaluation — Incomplete Evidence Pack (No TxGNN Predictions Available)

---

## One-Sentence Summary

Repaglinide (DB00912) is a meglitinide-class short-acting insulin secretagogue indicated for Type 2 Diabetes Mellitus. This Evidence Pack (v4, data cutoff 2026-04-20) contains **no TxGNN predicted indications**, which makes a standard repurposing evaluation impossible at this stage. Critical data gaps exist across MOA documentation, safety information, and Germany market status — all must be resolved before the evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Type 2 Diabetes Mellitus (meglitinide class insulin secretagogue; source: DrugBank DB00912) |
| Predicted New Indication | Not available — `predicted_indications` array is empty |
| TxGNN Prediction Score | Not available |
| Evidence Level | N/A |
| Germany Market Status | Not marketed (0 authorizations on record) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** — insufficient data to evaluate |

---

## Why Is This Evaluation Incomplete?

The Evidence Pack contains two blocking gaps that prevent a standard repurposing report from being generated:

**1. No TxGNN predicted indications.** The `predicted_indications` field is an empty array. Without a candidate disease target, none of the standard sections — clinical trial mapping, literature review, mechanistic rationale, or cytotoxicity assessment — can be populated. This may indicate the TxGNN pipeline has not yet run for this drug, or that results were filtered out before this pack was assembled.

**2. Mechanism of action (MOA) data is missing (DG002, severity: High).** Repaglinide is known to close ATP-sensitive potassium channels on pancreatic β-cells, stimulating glucose-dependent insulin secretion. However, this information is not present in the Evidence Pack and has been flagged as a data gap. The remediation path (DrugBank API query) has been identified but not yet executed.

**3. Safety data is entirely absent (DG001, severity: Blocking).** All `key_warnings`, `contraindications`, and DDI entries carry `[Data Gap]` or `not_found` status. This is classified as a Blocking gap in the meta section, meaning the pipeline should not advance to safety screening (S1) without first downloading and parsing the package insert PDF from the TFDA/BfArM official source.

---

## Germany Market Information

No marketing authorizations for Repaglinide are currently registered in this Evidence Pack. The `taiwan_regulatory` (BfArM) query returned 0 results on 2026-03-29.

> **Note:** Repaglinide-containing products (e.g., NovoNorm®) are approved in several markets globally. The absence of records here likely reflects a data sourcing gap rather than true non-approval. This should be verified directly against the BfArM product database before concluding "not marketed."

---

## Safety Considerations

All safety fields in this Evidence Pack are `[Data Gap]`. Per reporting rules, no safety items are listed.

> Please refer to the package insert for safety information. Specific attention should be paid to hypoglycaemia risk, hepatic impairment contraindication, and CYP2C8/CYP3A4-mediated drug interactions, which are well-established for this drug class.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is structurally incomplete — there are no TxGNN predictions to evaluate, and two blocking data gaps (safety data, MOA) prevent the evaluation pipeline from advancing to any downstream stage.

**To proceed, the following is needed:**

- [ ] **Re-run TxGNN pipeline** for Repaglinide (DB00912) and populate `predicted_indications` with at least the top-ranked disease candidates and their scores.
- [ ] **Resolve DG001 (Blocking):** Download and parse the Repaglinide package insert PDF from TFDA/BfArM to extract key warnings and contraindications.
- [ ] **Resolve DG002 (High):** Query the DrugBank API for the full MOA entry and populate `original_moa`.
- [ ] **Verify Germany market status:** Cross-check BfArM product database for NovoNorm® or equivalent Repaglinide authorizations; the current 0-count result is likely a data gap, not an actual regulatory absence.
- [ ] **Re-generate Evidence Pack** at v5+ once the above gaps are closed, then re-run this report template with populated `predicted_indications[0]`.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

